These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4238955)

  • 21. Clinical relevants of the membrane protective action of aprotinin on the intraoperative histamine liberation.
    Harke H; Rahman S
    Prog Clin Biol Res; 1989; 308():959-63. PubMed ID: 2476829
    [No Abstract]   [Full Text] [Related]  

  • 22. The inhibitory effect of sulfated schizophyllans and related oligosaccharides on coagulation and fibrinolysis.
    Hirata A; Nagamatsu Y; Itoh W; Tabata K; Yamamoto J; Okada Y
    Biol Pharm Bull; 1994 May; 17(5):739-41. PubMed ID: 7920446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia.
    Renckens R; Weijer S; de Vos AF; Pater JM; Meijers JC; Hack CE; Levi M; van der Poll T
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):483-8. PubMed ID: 14739127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of trasylol on fibrinolytic activity of tissues].
    Maliusina IB
    Farmakol Toksikol; 1969; 32(5):628-31. PubMed ID: 4243700
    [No Abstract]   [Full Text] [Related]  

  • 25. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin.
    Mannucci L; Gerometta PS; Mussoni L; Antona C; Parolari A; Salvi L; Biglioli P; Tremoli E
    Thromb Haemost; 1995 Mar; 73(3):356-61. PubMed ID: 7545317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proteolytic enzymes in leukocytes].
    Frydecka I
    Acta Haematol Pol; 1974; 5(1):73-7. PubMed ID: 4595061
    [No Abstract]   [Full Text] [Related]  

  • 28. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of heparin on the plasma fibrinolytic activity.
    Poplawski A; Glowínski S
    Acta Physiol Pol; 1974; 25(1):39-42. PubMed ID: 4281609
    [No Abstract]   [Full Text] [Related]  

  • 30. Disappearance of ellagic acid induced hyper-coagulability in the dog after trasylol administration.
    Girolami A; Brunetti A; Cella G; Pedrazzoli S; Bernardi R
    Thromb Diath Haemorrh; 1973 May; 29(2):384-92. PubMed ID: 4543444
    [No Abstract]   [Full Text] [Related]  

  • 31. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
    Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
    FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of dextran 70 on the action of the primary fibrinolysis inhibitor ("alpha2-plasmin inhibitor").
    Carlin G; Saldeen T
    Thromb Res; 1978 Apr; 12(4):681-6. PubMed ID: 149394
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of plasmin-mediated fibrinolysis by vitamin E.
    Moroz LA; Gilmore NJ
    Nature; 1976 Jan; 259(5540):235-7. PubMed ID: 129706
    [No Abstract]   [Full Text] [Related]  

  • 35. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of low dose aprotinin on reduction of blood loss after extracorpreal circulation].
    Takahashi K; Hoshino S; Iwaya F; Igari T; Satokawa H; Ono T; Takase S; Ogawa T; Satoh K; Satoh K; Misawa Y; Ishikawa K
    Kyobu Geka; 2000 Dec; 53(13):1085-90. PubMed ID: 11127552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Behavior of human plasmin inhibitors in intravascularly increased fibrinolytic activity].
    Fischer M
    Thromb Diath Haemorrh; 1970 Jun; 23(3):513-52. PubMed ID: 4247030
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of fibrinolytic and thromboplastic activity by Trasylol.
    Amris CJ
    Scand J Haematol; 1966; 3(1):19-32. PubMed ID: 4223779
    [No Abstract]   [Full Text] [Related]  

  • 39. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of proteinase/antiproteinase inhibitor disequilibrium in the bioincompatibility induced by artificial surfaces.
    Deppisch R; Haug U; Göhl H; Ritz E
    Nephrol Dial Transplant; 1994; 9 Suppl 3():17-23. PubMed ID: 7521027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.